Ashley Gallagher, Editor

These are used to help reduce inappropriate testing, where an expert consults with medical directors of infection prevention and control for a test-order override.

Individuals treated with the drugs from AstraZeneca demonstrate clinically meaningful and statistically significant improvement.

State-level respiratory syncytial virus hospitalization rates for 2022 could be the highest seen since 2006, analysis published in Frontiers in Pediatrics indicate.

Many long-term therapies rely solely on load amelioration, but new ones are needed, according to investigators.

Individuals who are rituximab-naïve remained stable after 2 years of follow-up, the analysis shows.

The patient had no significant past medical complications and was fully immunized for the age-based recommendation from the Advisory Council and Immunization Practices, study shows.

Women who are pregnant should continue or start treatment with alternative or preferred antiretroviral therapies for viral suppression, investigators suggest.

The disease is the continuation of new symptoms 3 months after the initial SARS-CoV-2 infection and at least lasting 2 months after infection, according to the health organization.

Study results show significant differences in pCR rates, but the differences were not subtype-specific.

Investigators analyze to see if there was an association of expected benefits and risk of vaccination.

Health benefits last for at least 5 years if shedding pounds occur via a lifestyle change program, the results of a research review show.

Additionally, study results show a clinically meaningful overall survival trend in the overall population among individuals with primary advanced or recurrent disease.

Investigators suggest that funding mechanisms and interpersonal support systems are unsustainable for long-term care.

This method has proven economically appealing, but further confirmation of these findings is needed, according to investigators.

Clinical trial findings show that olaparib, given in the neoadjuvant setting, was feasible with 100% of participants able to receive the planned 2 cycles.

Fomepizole, an FDA-approved drug to treat methanol poisoning, and erythromycin could offer a novel therapeutic option to fight drug-resistant S. pneumoniae.

Investigators suggest that sleep interventions may help to reduce the risk of self-harm in female adolescents with depression and anxiety.

The data underscore the need for biomarker testing to identify patients who may be eligible for this therapy, according to physician from Memorial Sloan Kettering Cancer Center.

Asian Americans often develop the disease at a normal weight, which would be overlooked by current screening guidelines, investigators say.

The drug from AstraZeneca and Ionis Pharmaceuticals demonstrates a sustained benefit through 66 weeks for those with hereditary transthyretin-mediated amyloid polyneuropathy.

The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.

Authorized for use in professional point-of-care settings, the nucleic acid amplification diagnostic tool delivers results in 25 minutes.

Regeneron and Sanofi’s Dupilumab is the first biologic to demonstrate a clinically meaningful and statistically significant reduction in exacerbations compared with the placebo.

Increased risk for severe disease in individuals with SUD could be from co-occurring medical conditions, investigators from Boston Medical Center say.

Data indicated that waist-to-height ratio is a better indicator of outcomes in patients with HF than body mass index.

Given the promising results, the company is advancing Rinvoq to a phase 3 clinical trial for the autoimmune disorder.

Ribociclib plus endocrine therapy demonstrates a reduction in the risk of disease recurrence in patients with HR+/HER2- early breast cancer.

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

Axicabtagene ciloleucel demonstrated a 2.5-fold increase in individuals with relapsed/refractory large B-cell lymphoma who were alive at 2 years and did not experience either cancer progression or require the need for additional cancer treatment.

Therapy from Karuna Therapeutics demonstrates an 8.4-point reduction in Positive and Negative Syndrome Scale total score compared with the placebo at week 5.